Bio2 Quick Facts
Bio2 Technologies has developed bone graft substitute products for the fast-growing markets of spine and foot and ankle surgery:
- Proprietary platform technology offering unique combination of bioactivity and strength at a low cost to manufacture.
- Our fully resorbable material exhibited excellent bioactivity and mechanical strength in pre-clinical testing.
- Basic material chemistry approved for clinical use since 1985.
- Maturing IP portfolio with five issued US, four issued China, two issued Japan and two issued Israel patents.
- Product pipeline targets two high growth product categories in orthopedics, spine and foot and ankle surgery.
- Our first implantable device received FDA clearance in December 2014.